So, in the current phase I/II clinical trials, tyrosine kinase inhibitors as sorafenib, have been used to inhibit tumor growth and angiogenesis by inhibiting the VEGF signaling pathway [10,11]. This evidence concerns the gene VEGFA and neoplasm.